GlassScriptPhysician profile
Joshua Llorente
NPI 1417516675
$562.08
in general payments reported to CMS, 2019-2025
15 companies · $194 in 2025
The $194 reported for 2025 was more than what 75% of Hospitalist providers received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $18.71 · 2020: $13.72 · 2021: $206 · 2022: $28.71 · 2024: $102 · 2025: $194.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $295.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $295.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $95.01 | 2025 | |
| Janssen Pharmaceuticals, INC | $82.53 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $73.41 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $59.75 | 2024-2025 | Capvaxive, Gardasil 9, Vaxneuvance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $47.83 | 2021 | |
| Exact Sciences Corporation | $44.81 | 2025 | The Cologuard Plus Collection Kit |
| Astrazeneca Pharmaceuticals LP | $29.52 | 2024 | Farxiga |
| Abbvie INC. | $20.69 | 2024 | |
| Acorda Therapeutics, INC | $18.71 | 2019 | |
| Novartis Pharmaceuticals Corporation | $15.61 | 2025 | |
| Therapeuticsmd, INC. | $15.33 | 2021 | |
| Glaxosmithkline, LLC. | $15.32 | 2024 | Shingrix, Arexvy |
| Novo Nordisk INC | $15.11 | 2021 | |
| Lilly USA, LLC | $14.73 | 2024 | Mounjaro |
| Astellas Pharma US INC | $13.72 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joshua Llorente listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.